Search
MoonLake Immunotherapeutics
MLTXAdd to Watchlist
12.270USD
-0.630-4.88%
Market hours 09/24, 14:34（ET）
1.01BMarket Cap
LossP/E TTM
MLTX Analyst Recommendation Trends
In the current month, MLTX has received 7 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. MLTX average Analyst price target in the last month is 31.500.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
5
5
6
6
5
5
4
4
7
7
7
7
6
6
6
6
2
2
2
2
3
4
6
6
1
1
1
1
2
2
2
2
1
1
1
1
1
1
0
0
16
16
17
17
17
18
18
18
Financial Forecasting
Based on analysts' estimates, MLTX EPS is projected to reach -0.783 in FY2026Q3, following reported EPS of -0.836 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.99
-0.89
-0.92
-0.78
-0.82
Actual
-0.92
-0.98
-0.84
--
--
Surprise
+7.16%
-9.66%
+8.98%
--
--
FAQs
How have MoonLake ImmunotherapeuticsMLTX's recent earnings per share performed?
The market expectation was USD -0.84, while MoonLake ImmunotherapeuticsMLTX's earnings per share (EPS) for the previous quarter was USD -0.98. EPS for the next quarter is expected at USD -0.78.
What is the analyst rating for MoonLake Immunotherapeutics?
Based on the ratings of MoonLake Immunotherapeutics's stock from 16 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.